Treatment of relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+PTLD)
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XL Antineoplastic cell and gene therapy
L01XL09 Tabelecleucel
D11146 Tabelecleucel (USAN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11146
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11146
